recent updates from the momentum trial and the value of momelotinib for the treatment of mf
Published 1 year ago • 118 plays • Length 1:53Download video MP4
Download video MP3
Similar videos
-
1:26
updates on the use of momelotinib for the treatment of mf & clinical trials evaluating this agent
-
2:48
updated results from the momentum trial
-
1:24
updated results from the momentum study assessing the efficacy of momelotinib in mf
-
2:50
insights into the ca057-003 trial: mezigdomide, tazemetostat & dexamethasone for r/r myeloma
-
3:48
trials of interest in newly diagnosed myeloma presented at ims 2024
-
2:03
an update on the phase ii/iii imerge trial of imetelstat in lr-mds
-
2:22
the need for novel agents to treat patients with mcl who have relapsed after targeted therapy
-
2:45
safety and efficacy of inotuzumab ozogamicin conditioning for allosct in lymphoid malignancies
-
5:01
keynote-522: final os findings of pembrolizumab and chemotherapy in tnbc
-
1:52
selecting and sequencing therapies in newly diagnosed myeloma
-
57:19
hematuria: evaluation with dr. stephen lieberman - december 13, 2023
-
1:23
the current landscape of treatment for hr-mds: an update from ash 2023
-
1:20
insights into the diagnosis of smoldering myeloma from a uk perspective & ongoing trials
-
2:49
results from the phase iii echo trial of acalabrutinib plus br in mcl
-
0:45
current landscape of treatment for scd: an update from ash 2023
-
1:48
an analysis of transfusion-related cost offsets & time burden in pts with mf in the momentum trial
-
2:01
the evolution of bcl2 inhibition in cll
-
1:18
updates from the monumental-1 trial
-
2:07
challenges associated with the management of extramedullary myeloma & ongoing research
-
11:42
thalassemia highlights at ash 2023: novel therapies, trial updates & the value of precision medicine
-
3:02
novel treatments and ongoing clinical trials for wm: targeted agents and immunotherapies
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis